Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Ralf Gold; Krzysztof Selmaj; Regina Berkovich; Jeffrey A. Cohen; G. Comi; Eva Havrdová; James K. Sheffield; Hetal Desai; Chun‐Yen Cheng; Jon Riolo; Andrew Thorpe; Erik DeBoer; Bruce Cree

doi:10.1002/acn3.70366

March 27, 2026Annals of Clinical and Translational NeurologyOpen Access

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate relapse activity following the discontinuation of ozanimod in multiple sclerosis patients.
Analyzed relapse rates within 90 days post ozanimod treatment cessation
Monitored participant responses and relapse cases
Most participants did not experience a relapse within 90 days of discontinuation
No evidence of a rebound effect after stopping ozanimod

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

Loading...

Member takes

Implication

Participants showed no significant relapse after stopping ozanimod, suggesting no rebound effect.

Abstract

Most participants did not relapse within 90 days following ozanimod discontinuation. Post-treatment relapse cases suggestive of a rebound effect were not observed.

Cite This Study

Gold et al. (2026) studied this question.

synapsesocial.com/papers/69c8c336de0f0f753b39dda1 https://doi.org/10.1002/acn3.70366

View Full Paper

Ask AI

Bookmark

Share

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Key Points

Ask about this paper

Discussion

Member takes

Implication

Abstract

Cite This Study

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Key Points

Ask about this paper

Discussion

Member takes

Implication

Abstract

Cite This Study

Keep reading

Keep reading